ArticleInternational journal of clinical and experimental pathology2018
Profilin-1 mediates microvascular endothelial dysfunction in diabetic retinopathy through HIF-1α-dependent pathway.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 14 citations in OpenAlex.
- Profilin and Its Isoforms: Unravelling the Functional Diversity Across Life Forms.Current protein & peptide science · 2026Review
- Review
- Article
- Blood-nerve barrier enhances chronic postsurgical pain via the HIF-1α/ aquaporin-1 signaling axis.BMC anesthesiology · 2023Article
- Vascular endothelial cell-specific disruption of thePNAS nexus · 2023Article
- Profilin1 Promotes Renal Tubular Epithelial Cell Apoptosis in Diabetic Nephropathy Through the Hedgehog Signaling Pathway.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- The role of profilin-1 in cardiovascular diseases.Journal of cell science · 2021Review
- Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function.Theranostics · 2021Review
- Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells.The Journal of biological chemistry · 2020Article
- Uncovering the protective mechanism of Taohong Siwu decoction against diabetic retinopathy via HIF-1 signaling pathway based on network analysis and experimental validation.BMC complementary medicine and therapies · 2020Article
- Disruption of profilin1 function suppresses developmental and pathological retinal neovascularization.The Journal of biological chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic retinopathy (DR), a well-known serious complication of diabetes mellitus, can eventually advance to end-stage blindness.
aimTo investigate the role of profilin-1 (PFN1) in microvascular endothelial dysfunction (MVED) triggered by DR.
methodsWe assessed the expression of PFN1 and hypoxia inducible factor-1 alpha (HIF-1α) in cultured human retinal microvascular endothelial cells (HRMECs) treated with high glucose and in 6 month-old Sprague-Dawley (SD) rats with DR. We also investigated the function of metformin in PFN1-mediated MVED.
resultsHigh glucose upregulated PFN1 and HIF-1α expression levels. These changes were associated with increased permeability, apoptosis, and angiogenesis
conclusionOur results indicate that activation of HIF-1α/PFN1 by high glucose mediates permeability, apoptosis, and angiogenesis and that metformin alleviates MVED by suppressing HIF-1α/PFN1 signaling during DR. These results suggest a potential therapeutic strategy for preventing the onset of PFN1 in early-stage of DR.
Indexed as
Identifiers
31938219PMC6958150W3026109179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.